This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: riociguat

October 2015 Br J Cardiol 2015;22:(4) Online First

Focus on pulmonary hypertension

BJCardio Staff

Abstract

(more…)

| Full text

March 2015 Br J Cardiol 2015;22:19

In brief

BJCardio Staff

Abstract

NICE NOAC guidance The National Institute for Health and Care Excellence (NICE) has recently published two recommendations on the use of novel oral anticoagulants (NOACs). NICE has recommended the NOAC dabigatran as an option for treating and preventing deep-vein thrombosis (DVT) and pulmonary embolism (PE) in adults (available in full at http://www.nice.org.uk/guidance/ta327) A final appraisal determination has also been issued for the NOAC rivaroxaban. It recommends it is an effective treatment option for preventing secondary events after acute coronary syndrome in patients with elevated cardiac biomarkers. Publication of full guidance is e

| Full text

March 2014 Br J Cardiol 2014;21:16

In brief

BJCardio Staff

Abstract

New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now